Skip to main content
. 2021 May 21;11:10676. doi: 10.1038/s41598-021-90115-8

Figure 1.

Figure 1

MSCs enhance and sustain intrinsic iTreg phenotype during IL-2 driven ex vivo expansion. (a) Schematic diagram shows experimental strategy for iTreg expansion. (b) Absolute number, percentage of FOXP3+, FOXP3 MFI in CD4 T cells and viability of CD4 T cells at day 21 were measured at indicated time points in IL-2/media vs MSC co-culture with identical IL-2/media (n = 6–7). Multiple comparisons analysis was performed using the Friedman test. (c) Absolute number of CD62L+ and CD45RA+ iTreg cells were calculated at 21 days expansion (n = 5–6). (d) Immuno-phenotyping of Treg marker expression on D0 naïve CD4 T cells, 7 days expanded naïve T cells in IL-2/media over MSC monolayer w/o CD3/CD28 stimulation (Day 7 naïve CD4—MSC co-culture), or 4 days stimulated CD4 T cells with TGF-β/IL-2 and CD3/28—(Day 4 iTreg CD4) and iTregs included surface staining with antibodies targeting CD25, CD152 (CTLA-4), CD223 (LAG-3), CD278 (ICOS) CD304 (NRP-1), CD279 (PD-1), CD366 (Tim-3), and TIGIT at 21 days expansion. Data are representative of three independent experiments ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 paired t test. See also Supplementary Fig. S1.